Professor Volker Diehl, of the University of Cologne, Germany, talks to ecancer managing editor Prof Gordon McVie at the 2010 German Cancer Conference (DKK), about personalised therapy for Hodgkin's lymphoma and the latest from his 30 year old Hodgkin's lymphoma study group. He suggests reducing both chemotherapy and radiotherapy for certain patients to prevent long term damaging effects, eg reducing the amount of ABVD (Adriamycin (doxorubicin), bleomycin, vinblastine, dacarbazine) used.